You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

What is Nucala?

Nucala is indicated as an add-on treatment for adult, adolescent and paediatric patients (aged 6 or above) with severe refractory eosinophilic asthma.1Nucala is administered as a subcutaneous injection at a fixed dose once every four weeks.1

How does Nucala work?

Nucala targets IL-5, the main cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. By inhibiting IL-5 signalling, Nucala reduces the production and survival of eosinophils.13

Who could benefit from Nucala?

*Fictional patient for discussion only.

Patients who are likely to benefit from Nucala should have two or more controller therapies, including high-dose ICS and additional controller(s) and two or more exacerbations in the previous 12 months and/or daily OCS.1

Nucala is recommended for long-term treatment and its use should be reviewed on an annual basis.1

Clinical response to Nucala is predicted in patients with eosinophil counts ≥150 cells/μL at initiation of treatment or ≥300 cells/μL in the prior 12 months.6

*Fictional patient for discussion only.


IL-5, interleukin-5.


  1. Nucala SmPC, 2018 Available at Last accessed Dec 2018.
  2. Wen T, Rothenberg ME. Microbiol Spectr 2016; doi: 10.1128/microbolspec.MCHD-0020-2015.
  3. Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746–760.
  4. Price D et al. J Asthma Allergy 2016; 9:1–12.
  5. Garcia G et al. Eur Respir Rev 2013; 22:251–257.
  6. Ortega HG et al. Lancet Respir Med 2016; 4:549–556.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at Adverse events can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Copyright © 2019 GlaxoSmithKline Group of Companies. All rights reserved. 
Nucala is a registered trademark of the GlaxoSmithKline Group of Companies.